<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004003</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067213</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-1993</secondary_id>
    <secondary_id>WSU-04-03-99-M01-FB</secondary_id>
    <secondary_id>NCI-G99-1553</secondary_id>
    <nct_id>NCT00004003</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Study of Gemcitabine, Cisplatin, and 5-Fluorouracil in the Treatment of Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      adult patients who have stage III or stage IV pancreatic cancer that cannot be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the overall survival in patients with unresectable stage III or IV&#xD;
      pancreatic adenocarcinoma treated with gemcitabine, cisplatin, and fluorouracil. II.&#xD;
      Determine the resectability rate with curative intent in patients with unresectable stage III&#xD;
      pancreatic adenocarcinoma treated with this regimen. III. Assess the tolerability and&#xD;
      toxicity of this treatment regimen in this patient population. IV. Evaluate this regimen in&#xD;
      terms of response rate, response duration, and overall time to disease progression in these&#xD;
      patients. V. Evaluate the quality of life in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15, followed by&#xD;
      cisplatin IV over 30 minutes on days 1 and 15. Patients receive fluorouracil as a continuous&#xD;
      infusion on days 1-15. Courses repeat every 28 days. Quality of life is assessed every 28&#xD;
      days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed pancreatic&#xD;
        adenocarcinoma Unresectable locally advanced (stage III) OR Metastatic (stage IV)&#xD;
        Gallbladder or biliary tract cancer allowed No endocrine tumors or lymphoma of the pancreas&#xD;
        No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0-2 Life expectancy: At least&#xD;
        12 weeks Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet count&#xD;
        greater than 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL AST no greater than&#xD;
        3.0 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Other: No&#xD;
        active infection No other serious systemic disorders No other active malignancies within&#xD;
        the past year except curatively treated basal cell skin cancer or carcinoma in situ of the&#xD;
        cervix Must have central venous access device (i.e., Infusaport or PASPORT) Not pregnant or&#xD;
        nursing Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        chemotherapy for locally advanced or metastatic disease At least 6 months since prior&#xD;
        adjuvant chemotherapy No prior gemcitabine Endocrine therapy: Not specified Radiotherapy:&#xD;
        Not specified Surgery: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A. Philip, MD, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

